Alector, Inc.

NASDAQ:ALEC

Biotechnology

Healthcare
$2.57 +5.13%

+$0.08 today

Market cap
$382.61M
Beta
0.59
P/E (TTM)
-1.4
EPS (TTM)
-$1.13
52W Low $1.09High $3.40

Volume 2.13M

Average 0.65M

ALEC Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Alector, Inc.NASDAQ: ALEC

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $2.08M rose 12.8% year over year, ahead of the +4.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 7.7% from the prior quarter. Over 3 fiscal years it compounded at +4.5% a year.

Context

  • Depreciation & amortization amounted to 45.9% of revenue in FY2025, up 37.1 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +12.8% holds above the trailing-twelve-month pace of +4.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.08M-7.7% QoQ
Last fiscal yearDec 2025
$9.66M+9.3% YoY
LTMMar 2026
$8.8M+4.8% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+12.8%——
1 year+9.3%——
3-year CAGR+4.5%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
9.66M USD
Year-over-year change
+9.3%
4-year CAGR
+3.8%

Depreciation & Amortization vs competitors

How ALEC compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +4.8% is the 3rd highest of 9, against a peer median of -14.1%.
  • Depreciation & amortization amounts to 47.8% of revenue for ALEC, versus a peer median of 99.1%.
ALEC Competitors
Depreciation & Amortization for ALEC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FATEFate Therapeutics, Inc.LTM Mar 2026$12.49M USD-28.5%-12.3%197.7%
NKTXNkarta, Inc.LTM Mar 2026$9.23M USD+0.4%+51.6%—
ALECAlector, Inc.LTM Mar 2026$8.8M USD+4.8%+4.5%47.8%
PEPGPepGen Inc.LTM Mar 2026$3.2M USD-40.7%+41.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 2.61M CHF+9.7%-3.5%—
VORVor Biopharma Inc.LTM Mar 2026$2.09M USD-38.7%-31.4%—
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$248K USD-57.2%-46.1%—
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$185K USD+3.4%+2.9%—
IRDOpus Genetics, Inc.LTM Mar 2026$53K USD+241.9%+136.6%0.4%
Peer median (excluding ALEC) —-14.1%-0.3%99.1%

Competitors are the stored peer set for ALEC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue207.09M133.62M97.06M100.56M21.05M
Cost of Revenue189.41M08.85M185.94M9.66M
Gross Profit17.68M133.62M88.21M(85.38M)11.38M
Gross Margin8.5%100.0%90.9%-84.9%54.1%
Research & Development189.41M210.42M192.12M209.24M123.07M
Selling, General & Admin55.04M61.03M56.69M57.41M53.99M
Operating Expenses55.04M271.45M239.95M59.62M157.19M
Depreciation & Amortization8.32M8.47M8.85M8.84M9.66M
EBITDA(28.01M)(121.58M)(116.33M)(110.08M)(133.1M)
EBITDA Margin-13.5%-91.0%-119.9%-109.5%-632.5%
Operating Income(37.36M)(137.83M)(151.74M)(145M)(145.81M)
Operating Margin-18.0%-103.2%-156.3%-144.2%-692.8%
Interest Income00000
Interest Expense00000
Other Income / Expenses1.03M7.78M26.56M26.08M3.05M
Income Before Tax(36.33M)(130.06M)(125.18M)(118.92M)(142.76M)
Pre-Tax Margin-17.5%-97.3%-129.0%-118.3%-678.4%
Income Tax Expense03.25M5.21M128K168K
Net Income(36.33M)(133.31M)(130.39M)(119.05M)(142.93M)
Net Margin-17.5%-99.8%-134.3%-118.4%-679.2%
EPS (Basic)(0.45)(1.62)(1.56)(1.23)(1.39)
EPS (Diluted)(0.45)(1.62)(1.56)(1.23)(1.39)
Weighted Avg Shares80.42M82.47M83.73M96.59M103M
Weighted Avg Shares (Diluted)80.42M82.47M83.73M96.59M103M

Alector, Inc.

NASDAQ:ALEC

Intrinsic Alpha fair value

Locked

Current Price

$2.57

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.